EC approves Reblozyl for transfusion-dependent anemia in myelodysplastic syndromes or beta thalassemia

This article was originally published here

Adult patients with transfusion-dependent anemia due to very low-, low- and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response or are ineligible for erythropoietin-based

The post EC approves Reblozyl for transfusion-dependent anemia in myelodysplastic syndromes or beta thalassemia appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply